Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.31
SPPI's Cash to Debt is ranked higher than
59% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. SPPI: 1.31 )
SPPI' s 10-Year Cash to Debt Range
Min: 0.2   Max: 17918
Current: 1.31

0.2
17918
Equity to Asset 0.56
SPPI's Equity to Asset is ranked higher than
64% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SPPI: 0.56 )
SPPI' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.95
Current: 0.56

0.2
0.95
F-Score: 3
Z-Score: 0.77
M-Score: -1.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -24.89
SPPI's Operating margin (%) is ranked higher than
76% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. SPPI: -24.89 )
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54   Max: 30.17
Current: -24.89

-68658.54
30.17
Net-margin (%) -39.87
SPPI's Net-margin (%) is ranked higher than
73% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. SPPI: -39.87 )
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24   Max: 35.19
Current: -39.87

-67890.24
35.19
ROE (%) -22.06
SPPI's ROE (%) is ranked higher than
71% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. SPPI: -22.06 )
SPPI' s 10-Year ROE (%) Range
Min: -2624.11   Max: 32.63
Current: -22.06

-2624.11
32.63
ROA (%) -12.45
SPPI's ROA (%) is ranked higher than
74% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. SPPI: -12.45 )
SPPI' s 10-Year ROA (%) Range
Min: -510.69   Max: 18.66
Current: -12.45

-510.69
18.66
ROC (Joel Greenblatt) (%) -2526.71
SPPI's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. SPPI: -2526.71 )
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5194.83   Max: 3170.09
Current: -2526.71

-5194.83
3170.09
Revenue Growth (%) 19.70
SPPI's Revenue Growth (%) is ranked higher than
89% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SPPI: 19.70 )
SPPI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 211.9
Current: 19.7

0
211.9
EBITDA Growth (%) -34.00
SPPI's EBITDA Growth (%) is ranked higher than
58% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. SPPI: -34.00 )
SPPI' s 10-Year EBITDA Growth (%) Range
Min: -70.9   Max: 108.9
Current: -34

-70.9
108.9
EPS Growth (%) 2.40
SPPI's EPS Growth (%) is ranked higher than
84% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SPPI: 2.40 )
SPPI' s 10-Year EPS Growth (%) Range
Min: -71.4   Max: 131.1
Current: 2.4

-71.4
131.1
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SPPI Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q3 2013

SPPI Guru Trades in Q3 2013

Jim Simons 12,017 sh (New)
» More
Q4 2013

SPPI Guru Trades in Q4 2013

Paul Tudor Jones 13,000 sh (New)
Jim Simons 69,517 sh (+478.49%)
» More
Q1 2014

SPPI Guru Trades in Q1 2014

Jim Simons 171,307 sh (+146.42%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.13%$10.64 - $12.31 $ 7.2-37%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.2-37%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.2-37%0
John Burbank 2012-09-30 New Buy0.13%$11.6 - $17.05 $ 7.2-48%250000
Joel Greenblatt 2012-09-30 New Buy0.02%$11.6 - $17.05 $ 7.2-48%19901
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
SPPI's P/B is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. SPPI: 1.70 )
SPPI' s 10-Year P/B Range
Min: 0.54   Max: 5.23
Current: 1.7

0.54
5.23
P/S 2.80
SPPI's P/S is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. SPPI: 2.80 )
SPPI' s 10-Year P/S Range
Min: 1.07   Max: 367
Current: 2.8

1.07
367
EV-to-EBIT -7.37
SPPI's EV-to-EBIT is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: -7.37 )
SPPI' s 10-Year EV-to-EBIT Range
Min: 5.6   Max: 63.5
Current: -7.37

5.6
63.5
Current Ratio 2.72
SPPI's Current Ratio is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. SPPI: 2.72 )
SPPI' s 10-Year Current Ratio Range
Min: 0.56   Max: 16.82
Current: 2.72

0.56
16.82
Quick Ratio 2.55
SPPI's Quick Ratio is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. SPPI: 2.55 )
SPPI' s 10-Year Quick Ratio Range
Min: 0.56   Max: 16.8
Current: 2.55

0.56
16.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.80
SPPI's Price/Tangible Book is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. SPPI: 21.80 )
SPPI' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 190.1
Current: 21.8

0.66
190.1
Price/DCF (Projected) 2.20
SPPI's Price/DCF (Projected) is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: 2.20 )
SPPI' s 10-Year Price/DCF (Projected) Range
Min: 1.53   Max: 12.51
Current: 2.2

1.53
12.51
Price/Median PS Value 0.60
SPPI's Price/Median PS Value is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. SPPI: 0.60 )
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 1970
Current: 0.6

0.12
1970
Earnings Yield (Greenblatt) 3.80
SPPI's Earnings Yield (Greenblatt) is ranked higher than
65% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. SPPI: 3.80 )
SPPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 17.7
Current: 3.8

1.6
17.7
Forward Rate of Return (Yacktman) 0.29
SPPI's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. SPPI: 0.29 )
SPPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: 0.5
Current: 0.29

-9.6
0.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany
Spectrum Pharmaceuticals Inc is a Delaware corporation that was originally incorporated in Colorado as Americus Funding Corporation in December 1987, became NeoTherapeutics, Inc. in August 1996, was reincorporated in Delaware in June 1997, and was renamed Spectrum Pharmaceuticals, Inc. in December 2002. The Company is a biotechnology company integrated with commercial and drug development operations primarily in hematology and oncology. It markets three oncology drugs, FUSILEV , FOLOTYN and ZEVALIN and also market ZEVALIN outside of the U.S. The Company has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including formulation development, clinical development, medical affairs, regulatory affairs, biostatistics and data management, and has established a commercial infrastructure for the marketing of its drug products. The Company product portfolio is consist of both commercial stage and development stage products. The Company's products are manufactured on a contract basis. It has built and develop, a sales and marketing infrastructure as part of its commercialization efforts for FUSILEV, ZEVALIN and FOLOTYN. The Company have limited number of customers which include Oncology Supply, McKesson Specialty, ICS and Cardinal Health. The Company competes with Abraxis Bioscience, Inc., Astra Zeneca LP, Bayer AG, Endo Pharmaceuticals, Eli Lilly and Co., Novartis Pharmaceuticals, Corporation, Genentech, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Cephalon, Inc., Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., Roche Pharmaceuticals and Johnson & Johnson. The development, production and marketing of the company's proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
http://seekingalpha. Aug 14 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Spectrum Pharma upgraded by R. F. Lafferty Jul 15 2014
Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon Jul 09 2014
Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq Jul 07 2014
Spectrum receives accelerated FDA approval for Beleodaq Jul 07 2014
Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning Jul 07 2014
FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection Jul 07 2014
Spectrum Pharmaceuticals granted accelerated approval of lymphoma treatment Jul 07 2014
FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection Jul 07 2014
FDA approves lymphoma drug from Spectrum Pharma Jul 03 2014
FDA approves lymphoma drug from Spectrum Pharma Jul 03 2014
Spectrum Pharma Lymphoma Drug Approved Early Jul 03 2014
Midday movers: Lorillard, PetSmart, Walgreen & More Jul 03 2014
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI) Jul 03 2014
FDA approves Spectrum Pharma's blood cancer drug Jul 03 2014
Spectrum confirms FDA approves Beleodaq, updates on PMRs for Beleodaq, Folotyn Jul 03 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Triggering Events That... Jul 03 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide